Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional

Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)

ClinicalTrials.gov ID: NCT06291376

Public ClinicalTrials.gov record NCT06291376. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 1, 2026, 10:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants With Immunoglobulin A Nephropathy (IgAN)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary objective of this study to evaluate efficacy of ravulizumab compared with placebo on proteinuria reduction and change in eGFR in adult participants with IgAN who are at risk of disease progression.

Study identification

NCT ID
NCT06291376
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Enrollment
579 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 28, 2024
Primary completion
Jan 4, 2026
Completion
Jul 18, 2030
Last update posted
Jun 21, 2026

2024 – 2030

United States locations

U.S. sites
39
U.S. states
16
U.S. cities
33
Facility City State ZIP Site status
Research Site Alabaster Alabama 35007
Research Site Phoenix Arizona 85054
Research Site Los Angeles California 90022
Research Site Los Angeles California 90027
Research Site Los Angeles California 90095
Research Site Orange California 92868
Research Site San Bernardino California 92408
Research Site San Diego California 92120
Research Site San Francisco California 94143
Research Site Stanford California 94305
Research Site Torrance California 90502
Research Site Valencia California 91355
Research Site Bay Pines Florida 33744
Research Site Miami Florida 33136
Research Site Orlando Florida 32806
Research Site Acworth Georgia 30101
Research Site Atlanta Georgia 30322
Research Site Lawrenceville Georgia 30046
Research Site New Orleans Louisiana 70121
Research Site Boston Massachusetts 02111
Research Site Boston Massachusetts 02114
Research Site Boston Massachusetts 02115
Research Site Worcester Massachusetts 01655
Research Site Minneapolis Minnesota 55435
Research Site Minneapolis Minnesota 55455
Research Site Kansas City Missouri 64111
Research Site North Las Vegas Nevada 89086
Research Site Albany New York 12208
Research Site New York New York 10016
Research Site The Bronx New York 10468
Research Site Columbus Ohio 43210
Research Site Knoxville Tennessee 37920
Research Site Arlington Texas 76002
Research Site Houston Texas 77030
Research Site Houston Texas 77054
Research Site San Antonio Texas 78229
Research Site Shenandoah Texas 77384
Research Site Charlottesville Virginia 22908
Research Site Milwaukee Wisconsin 53226

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 207 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06291376, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 21, 2026 · Synced Sep 1, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06291376 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →